enVVeno Medical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVNO research report →
Price Chart
About the company
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency.
- CEO
- Robert A. Berman
- IPO
- 2018
- Employees
- 33
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on NVNO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $171.47K
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.34
- EV/EBITDA
- 0.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -62.28%
- ROIC
- -79.12%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-20,899,000
- Net Income
- $-19,472,000+10.8%
- EPS
- $-33.06+97.9%
- OCF Growth
- +7.5%
- FCF Growth
- +7.7%
- 52W High
- $39.20
- 52W Low
- $8.67
- 50D MA
- $10.67
- 200D MA
- $11.69
- Beta
- 1.09
- RSI (14)
- 46
- Avg Volume
- 15.55K
No earnings-call transcripts are available for NVNO yet.
- Free Float
- 73.8%
- Shares Outstanding
- 16.50K
- Float Shares
- 12.18K
of shares held by institutions
37 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 299.25K | ▼ 561.95K |
| Wolverine Trading, LLC | 18.34K | ▲ 7.08K |
| Two Sigma Advisers, LP | 14.00K | ▲ 14.00K |
| Cibc Private Wealth Group, LLC | 860 | 0 |
Held by 5 ETFs
Biggest fund positions in NVNO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Duhay Francis | sell | 140 |
| Mar 12, 26 | Duhay Francis | sell | 140 |
| Dec 16, 25 | BERMAN ROBERT ANDREW | other | 200,000 |
| Dec 16, 25 | Alavi Hamed | other | 50,000 |
| Dec 16, 25 | Glickman Marc H. | other | 100,000 |
| Dec 11, 25 | Duhay Francis | other | 135,883 |
| Dec 11, 25 | Gray Robert | other | 135,883 |
| Dec 11, 25 | Jenusaitis Matthew | other | 135,883 |
| Dec 11, 25 | Shrivastava Sanjay | other | 135,883 |
| Dec 11, 25 | Duhay Francis | sell | 4,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVNO coverage
Recent articles, reports, and earnings notes.
No research on NVNO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVNO report →Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
accessnewswire.com · Aug 4
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
accessnewswire.com · Jul 31
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
accessnewswire.com · Jul 15
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
accessnewswire.com · Jul 7
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
accessnewswire.com · Jun 22
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
accessnewswire.com · Jun 2
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
accessnewswire.com · May 12
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
accessnewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.